Literature DB >> 23770856

Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.

C C Jiang1, A Croft2, H-Y Tseng1, S T Guo3, L Jin4, P Hersey4, X D Zhang5.   

Abstract

Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 3'-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF(V600E) melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF(V600E) or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770856     DOI: 10.1038/onc.2013.237

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

Review 2.  Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Authors:  Gregory R Kardos; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2015-09       Impact factor: 4.693

3.  miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.

Authors:  Fang Liu; Xuefeng Wang; Jiebing Li; Kuo Gu; Liyan Lv; Shuai Zhang; Dehai Che; Jingyan Cao; Shi Jin; Yan Yu
Journal:  Cell Prolif       Date:  2015-08-06       Impact factor: 6.831

Review 4.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.

Authors:  Szu-Mam Liu; Jean Lu; Hoong-Chien Lee; Feng-Hsiang Chung; Nianhan Ma
Journal:  Oncotarget       Date:  2014-10-15

6.  Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.

Authors:  Yi Lun Liu; Fritz Lai; James S Wilmott; Xu Guang Yan; Xiao Ying Liu; Qi Luan; Su Tang Guo; Chen Chen Jiang; Hsin-Yi Tseng; Richard A Scolyer; Lei Jin; Xu Dong Zhang
Journal:  Oncotarget       Date:  2014-11-30

7.  Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.

Authors:  Yan Zhou; Shuchen Lin; Kuo-Fu Tseng; Kun Han; Yaling Wang; Zhi-Hua Gan; Da-Liu Min; Hai-Yan Hu
Journal:  BMC Cancer       Date:  2016-10-21       Impact factor: 4.430

8.  The landscape of BRAF transcript and protein variants in human cancer.

Authors:  Andrea Marranci; Zhijie Jiang; Marianna Vitiello; Elena Guzzolino; Laura Comelli; Samanta Sarti; Simone Lubrano; Cinzia Franchin; Ileabett Echevarría-Vargas; Andrea Tuccoli; Alberto Mercatanti; Monica Evangelista; Paolo Sportoletti; Giorgio Cozza; Ettore Luzi; Enrico Capobianco; Jessie Villanueva; Giorgio Arrigoni; Giovanni Signore; Silvia Rocchiccioli; Letizia Pitto; Nicholas Tsinoremas; Laura Poliseno
Journal:  Mol Cancer       Date:  2017-04-28       Impact factor: 27.401

9.  INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.

Authors:  Meng Na Chi; Su Tang Guo; James S Wilmott; Xiang Yun Guo; Xu Guang Yan; Chun Yan Wang; Xiao Ying Liu; Lei Jin; Hsin-Yi Tseng; Tao Liu; Amanda Croft; Hubert Hondermarck; Richard A Scolyer; Chen Chen Jiang; Xu Dong Zhang
Journal:  Oncotarget       Date:  2015-11-24

10.  Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.

Authors:  Timothy Budden; Andre van der Westhuizen; Nikola A Bowden
Journal:  BMC Cancer       Date:  2018-01-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.